Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases
Abstract Introduction This study aims to evaluate the ocular and systemic safety profiles of intravitreal biosimilar ranibizumab Ranieyes (Lupin Pharmaceuticals, Mumbai, India) in real-world clinical settings across multiple chorioretinal vascular diseases, including neovascular age-related macular...
Saved in:
Main Authors: | Debdulal Chakraborty, Tushar Kanti Sinha, Sourav Sinha, Aniruddha Maiti, Angshuman Mukherjee, Krishnendu Nandi, Sudipta Das, Saptorshi Majumdar, Dinesh Rungta, Ranabir Bhattacharya |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-11-01
|
Series: | Ophthalmology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40123-024-01065-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Firework-Related Chorioretinitis Sclopetaria: A Case Report and Literature Review
by: Greta Kazlauskaitė, et al.
Published: (2023-11-01) -
Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01) -
Comparison of OCT Angiography Parameters after Administration of Intravitreal Brolucizumab versus Ranibizumab in Exudative Age-related Macular Degeneration
by: Sanjitha Vilma Moses, et al.
Published: (2024-12-01) -
CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)